• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    3/21/22 6:19:50 PM ET
    $ADMP
    $AGTC
    $ALLR
    $BIMI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADMP alert in real time by email

    Gainers

    • Allarity Therapeutics (NASDAQ:ALLR) stock rose 25.3% to $2.84 during Monday's after-market session. The market value of their outstanding shares is at $22.9 million.
    • DarioHealth (NASDAQ:DRIO) stock rose 15.4% to $7.49. The market value of their outstanding shares is at $162.0 million. The company's, Q4 earnings came out today.
    • Stealth BioTherapeutics (NASDAQ:MITO) stock rose 9.11% to $0.73. The market value of their outstanding shares is at $42.0 million.
    • Regulus Therapeutics (NASDAQ:RGLS) shares increased by 9.05% to $0.3. The market value of their outstanding shares is at $43.7 million.
    • NexGel (NASDAQ:NXGL) stock rose 8.87% to $2.27. The market value of their outstanding shares is at $12.6 million. The company's, Q4 earnings came out today.
    • CinCor Pharma (NASDAQ:CINC) shares moved upwards by 7.96% to $16.0. The company's market cap stands at $584.3 million.

    Losers

    • Statera BioPharma (NASDAQ:STAB) stock fell 29.3% to $0.42 during Monday's after-market session. Trading volume for this security closed at 443.1K, accounting for 61.8% of its average full-day volume over the last 100 days. The company's market cap stands at $15.0 million.
    • Applied Genetic (NASDAQ:AGTC) shares fell 23.34% to $1.38. This security traded at a volume of 369.5K shares come close, making up 82.1% of its average volume over the last 100 days. The company's market cap stands at $59.2 million.
    • Adamis Pharmaceuticals (NASDAQ:ADMP) shares fell 6.17% to $0.6. Adamis Pharmaceuticals's trading volume hit 352.1K shares by close, accounting for 20.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $89.3 million.
    • Immuneering (NASDAQ:IMRX) stock declined by 5.65% to $6.85. The market value of their outstanding shares is at $180.6 million.
    • Orphazyme (NASDAQ:ORPH) shares declined by 5.31% to $0.8. This security traded at a volume of 309.4K shares come close, making up 22.6% of its average volume over the last 100 days. The company's market cap stands at $28.2 million.
    • BIMI International (NASDAQ:BIMI) stock decreased by 5.15% to $1.29. The market value of their outstanding shares is at $10.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMP
    $AGTC
    $ALLR
    $BIMI

    CompanyDatePrice TargetRatingAnalyst
    Immuneering Corporation
    $IMRX
    10/31/2025$15.00Outperform
    Leerink Partners
    Allarity Therapeutics Inc.
    $ALLR
    7/28/2025$9.00Buy
    Ascendiant Capital Markets
    Regulus Therapeutics Inc.
    $RGLS
    3/27/2025$3.00 → $6.00Equal Weight → Overweight
    Wells Fargo
    DarioHealth Corp.
    $DRIO
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    Immuneering Corporation
    $IMRX
    12/13/2024Equal-Weight → Underweight
    Morgan Stanley
    Regulus Therapeutics Inc.
    $RGLS
    8/2/2024$7.00Outperform
    Oppenheimer
    Regulus Therapeutics Inc.
    $RGLS
    3/18/2024$6.00Outperform
    Leerink Partners
    Immuneering Corporation
    $IMRX
    3/15/2024$20.00 → $15.00Buy
    Needham
    More analyst ratings

    $ADMP
    $AGTC
    $ALLR
    $BIMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Immuneering with a new price target

    Leerink Partners initiated coverage of Immuneering with a rating of Outperform and set a new price target of $15.00

    10/31/25 8:20:02 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendiant Capital Markets initiated coverage on Allarity Therapeutics with a new price target

    Ascendiant Capital Markets initiated coverage of Allarity Therapeutics with a rating of Buy and set a new price target of $9.00

    7/28/25 8:53:33 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regulus Therapeutics upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Regulus Therapeutics from Equal Weight to Overweight and set a new price target of $6.00 from $3.00 previously

    3/27/25 1:44:29 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AGTC
    $ALLR
    $BIMI
    SEC Filings

    View All

    Allarity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    4/1/26 8:54:39 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by NexGel Inc

    10-K - NEXGEL, INC. (0001468929) (Filer)

    3/31/26 5:31:11 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by DarioHealth Corp.

    424B5 - DarioHealth Corp. (0001533998) (Filer)

    3/30/26 6:14:55 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $ADMP
    $AGTC
    $ALLR
    $BIMI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Brakewood Harold Eugene bought $24,990 worth of shares (5,250 units at $4.76), increasing direct ownership by 91% to 11,050 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/21/26 9:09:57 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schall Thomas J. bought $101,041 worth of shares (21,645 units at $4.67), increasing direct ownership by 41% to 74,530 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/20/26 9:17:29 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought $10,502 worth of shares (2,298 units at $4.57), increasing direct ownership by 0.61% to 376,496 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/16/26 4:07:43 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AGTC
    $ALLR
    $BIMI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity

    LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its fourth quarter and fiscal year 2025 financial results conference call to April 8, 2026 at 4:30 P.M. ET to provide additional time for the Company to provide shareholders with greater detail regarding its previously announced proposed transaction with Celularity Inc. The Company will file its Annual Report on Form 10-K for the year ended December 31, 2025, with the

    3/31/26 4:12:54 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

         Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2

    3/31/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st

    Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, after the market close on March 31, 2026. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Fourth Quarter and Full Year 2025 Financial Results Conf

    3/25/26 9:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $ADMP
    $AGTC
    $ALLR
    $BIMI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZIMHI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer

    10/18/21 11:55:40 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SYMJEPI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling

    6/30/21 5:11:48 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AGTC
    $ALLR
    $BIMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF PEOPLE OFFICER Neufeld Leah R was granted 3,628 shares, increasing direct ownership by 14% to 29,598 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    3/17/26 4:46:41 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF LEGAL OFFICER, SECRETARY Bookman Michael

    4 - Immuneering Corp (0001790340) (Issuer)

    2/5/26 8:44:51 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Business Officer Brakewood Harold Eugene

    4 - Immuneering Corp (0001790340) (Issuer)

    2/5/26 8:37:55 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AGTC
    $ALLR
    $BIMI
    Leadership Updates

    Live Leadership Updates

    View All

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor

    LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that NexGelRx, the Company's previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC. In connection with the investment, NexGelRx has appointed Mr. Gruntfest to serve as a board observer and advisor, bringing deep experience in reimbursement strategy, patient access, and healthca

    12/16/25 8:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder and longtime CEO and Chairman of ChemoCentryx, where he led the development and eventual FDA approval of Tavneos®, a first-in-class oral therapy for ANCA-associated vasculitis. Under his leadership, ChemoCentryx was acquired by Amgen in 2022 for nearly $4 billion. His career

    9/16/25 7:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AGTC
    $ALLR
    $BIMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    12/13/24 4:05:12 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

    SC 13G/A - Regulus Therapeutics Inc. (0001505512) (Subject)

    11/14/24 5:46:12 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

    SC 13G/A - Regulus Therapeutics Inc. (0001505512) (Subject)

    11/14/24 4:32:07 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AGTC
    $ALLR
    $BIMI
    Financials

    Live finance-specific insights

    View All

    NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity

    LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its fourth quarter and fiscal year 2025 financial results conference call to April 8, 2026 at 4:30 P.M. ET to provide additional time for the Company to provide shareholders with greater detail regarding its previously announced proposed transaction with Celularity Inc. The Company will file its Annual Report on Form 10-K for the year ended December 31, 2025, with the

    3/31/26 4:12:54 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

         Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2

    3/31/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st

    Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, after the market close on March 31, 2026. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Fourth Quarter and Full Year 2025 Financial Results Conf

    3/25/26 9:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care